Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence

被引:27
作者
de Juan Jimenez, Inmaculada [1 ]
Garcia Casado, Zaida [2 ]
Palanca Suela, Sarai [1 ]
Esteban Cardenosa, Eva [1 ]
Lopez Guerrero, Jose Antonio [2 ]
Segura Huerta, Angel [3 ]
Chirivella Gonzalez, Isabel [4 ]
Sanchez Heras, Ana Beatriz [5 ]
Juan Fita, Ma Jose [6 ]
Tena Garcia, Isabel [7 ]
Guillen Ponce, Carmen [5 ]
Martinez de Duenas, Eduardo [7 ]
Romero Noguera, Ignacio [6 ]
Salas Trejo, Dolores [8 ]
Goicoechea Saez, Mercedes [8 ]
Bolufer Gilabert, Pascual [1 ]
机构
[1] Hosp Univ La Fe, Escuela Enfermeri 7A, Serv Clin Anal, Mol Biol Lab, Valencia 46009, Spain
[2] Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain
[3] Hosp La Fe, Genet Counseling Unit, E-46009 Valencia, Spain
[4] Clin Hosp, Genet Counseling Unit, Valencia, Spain
[5] Hosp Elche, Genet Counseling Unit, Alicante, Spain
[6] Inst Valenciano Oncol, Genet Counseling Unit, Valencia, Spain
[7] Hosp Gen Castellon, Genet Counseling Unit, Castellon de La Plana, Spain
[8] Conselleria Sanitat, Canc Plan Off, Dept Publ Hlth, Valencia, Spain
关键词
Hereditary breast and ovarian cancer (HBOC); BRCA1; BRCA2; Recurrent mutations; Novel mutations; Relationship genotype-phenotype; BRCA2; MUTATIONS; GERMLINE MUTATIONS; HIGH PROPORTION; POPULATION; HAPLOTYPE;
D O I
10.1007/s10689-013-9622-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
During the first 6 years of the Program of Genetic Counselling in Cancer of Valencia (eastern Spain), 310 mutations (155 in BRCA1 and 155 in BRCA2) in 1,763 hereditary breast (BC) and ovarian cancer (OC) families were identified. Of the mutations found 105 were distinct (53 in BRCA1 and 52 in BRCA2), eight new and 37 recurrent. Two of the novel mutations were frame-shift placed in exons 2 and 11 of BRCA1 and the remaining six were placed in BRCA2; four frame-shift (three in exon 11 and one in exon 23), one deletion of the entire exon 19 and one in the intervening sequence of exon 22. The BRCA1 mutations with higher recurrence were c.66_68delAG, c.5123C > A, c.1961delA, c.3770_3771delAG and c.5152+5G > A that covered 45.2 % of mutations of this gene. The age of onset of BCs of c.68_69delAG mutation carriers occurs later than for the other recurrent mutations of this gene (45 vs. 37 years; p = 0.008). The BRCA2 mutations with higher recurrence were c.9026_9030delATCAT, c.3264insT and c.8978_8991del14 which represented 43.2 % of all mutations in this gene, being the most recurrent mutation by far c.9026_9030delATCAT that represents 21.3 % of BRCA2 mutations and 10.6 % of all mutations. Probands with family histories of BC and OC, or OC and/or BC in at least two first degree relatives, were the more likely to have BRCA1/BRCA2 mutations (35.2 % of the total mutations). And that most BRCA1mutations (73.19 % mutations) occurred in probands with early-onset BC or with family history of OC.
引用
收藏
页码:767 / 777
页数:11
相关论文
共 34 条
[21]  
Llort Gemma, 2002, Hum Mutat, V19, P307, DOI 10.1002/humu.9014.abs
[22]   Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer [J].
Loman, N ;
Johannsson, O ;
Kristoffersson, U ;
Olsson, H ;
Borg, Å .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (16) :1215-1223
[23]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71
[24]   Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain):: two novel truncating mutations and a large genomic deletion in BRCA1 [J].
Miramar, M. D. ;
Calvo, M. T. ;
Rodriguez, A. ;
Anton, A. ;
Lorente, F. ;
Barrio, E. ;
Herrero, A. ;
Burriel, J. ;
de Jalon, A. Garcia .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (02) :353-358
[25]  
Neuhausen SL, 1996, AM J HUM GENET, V58, P271
[26]   Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families:: Results of an international study [J].
Neuhausen, SL ;
Godwin, AK ;
Gershoni-Baruch, R ;
Schubert, E ;
Garber, J ;
Stoppa-Lyonnet, D ;
Olah, E ;
Csokay, B ;
Serova, O ;
Lalloo, F ;
Osorio, A ;
Stratton, M ;
Offit, K ;
Boyd, J ;
Caligo, MA ;
Scott, RJ ;
Schofield, A ;
Teugels, E ;
Schwab, M ;
Cannon-Albright, L ;
Bishop, T ;
Easton, D ;
Benitez, J ;
King, MC ;
Ponder, BAJ ;
Weber, B ;
Devilee, P ;
Borg, A ;
Narod, SA ;
Goldgar, D .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (06) :1381-1388
[27]  
Neuhausen SL, 1999, CANCER-AM CANCER SOC, V86, P2575, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.3.CO
[28]  
2-6
[29]   Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification [J].
Schouten, JP ;
McElgunn, CJ ;
Waaijer, R ;
Zwijnenburg, D ;
Diepvens, F ;
Pals, G .
NUCLEIC ACIDS RESEARCH, 2002, 30 (12) :e57
[30]  
Szabo CI, 1997, AM J HUM GENET, V60, P1013